[Cycloferon efficacy in treatment of upper respiratory tract infections: systematic review and meta-analysis]. / Klinicheskaia éffektivnost' tsikloferona pri infektsiiakh verkhnikh dykhatel'nykh putei. Sistematicheskii obzor i metaanaliz.

Medical scientific sources about randomized clinical trials of Cycloferon were studied as a single plot of 531 articles. AIM was to get the generalized cycloferon efficacy's assessment in comparison with basic therapies curing the otorhinolaryngologic diseases. Groups heterogeneity and responding parameters' variability were estimated also. Comparison groups were symmetric enough to annihilate end-point variabilities, so the results' interpretations were clear enough and vector of clinical effects was detectable. Comparison groups were integrated to increase statistical power of metaanalysis. In result, cycloferon additional administration in treatment of otorhinolaryngologic diseases added 25% to absolute and relative usefulness of medical intervention. Also cycloferon increased 3,5 times the chances of recovery and absence of recurrent exacerbation.

[Clinical efficacy of the immunomodulatory agent cycloferon (tablets) in viral respiratory infections: Results of a systematic review and meta-analysis]. / Klinicheskaia éffektivnost' immunomoduliatora tsikloferona (tabletki) pri virusnykh infektsiiakh organov dykhaniia: rezul'taty sistematicheskogo obzora i metaanaliza.

The authors carried out a systematic review and subsequent meta-analysis of randomized clinical trials evaluating the efficacy of the immunomodulator agent cycloferon as tablets in adults and children with viral respiratory diseases. A total estimate of its clinical efficacy was obtained in terms of compared heterogeneous groups and response variables. The data published in 16 articles were used to calculate the formal parameters of the clinical efficacy of cycloferon (increased absolute and relative benefits, odds ratio (OR); the number of patients needed to be additionally treated with cycloferon to achieve a favorable outcome or to prevent a poor outcome in one patient, etc.). High heterogeneity hampered the unequivocal interpretation of results; however, combining the compared homogeneous groups in the meta-analysis (with adjustments for fixed and random effects) increased the statistical power of the investigation. In children aged 6 to 18 years, the OR for the positive effect of the drug (no new cases after its preventive administration) was 5.3 (95% confidence interval (CI), 4.8-5.9), heterogeneity test, χ2 = 249.5; p=0.000...; I2 = 94.8% (95% CI, 92.7-96.3%). This suggested the heterogeneity of clinical trial data and extrapolated this estimate to medical practice. The use of cycloferon in adults to treat acute respiratory viral infection enhanced their chances of enduring the disease in a mild form and avoiding serious complications: the OR for positive outcomes was 9.7 (95% CI, 7.0-13.0), while the effect was more homogeneous than in children (heterogeneity test, χ2 = 7.4; p=0.061...; I2 = 59.4% (95% CI, 0-86.5). Thus, the use of cycloferon to treat and prevent acute viral respiratory infections showed a more than 5-fold increase in the probability of avoiding the disease or enduring the latter in a mild form.

[ADJUVANT ENERGY PROTECTION WITH REAMBERIN IN PRACTICE OF INTENSIVE CARE AND RESUSCITATION: META-ANALYSIS DATA ABOUT EFFECTIVENESS (SYSTEMATIC REVIEW).]

THE AIM: a synthesis of evaluations ofReamberin's clinical efficacy as energy protectorfor the results of a meta-analysis of published data obtained during controlled clinical studies with the same design and a high level of evidence. MATERIALS AND METHODS: To estimate succinic acid based remedy for infusions (reamberin), the meta-analysis was undertaken with data of reamberin use in intensive care, resuscitation departments, in critical post surgery period, in oncology (multiple chemotherapy of tumors), in emergent toxicology and pediatrics. 32 controlled randomized trials and all together 6221 patients were included. RESULTS: Unified indicators of clinical efficiency were systemically and thoroughly processed with advanced statistic tools, resulting data were sufficient for association and assessment of their heterogeneity in different articles. The adjuvant effects of reamberin were proven, as good outcome frequency enlarged more than by 25%, absolute and relative treatment benefits increased more than by 50%, positive outcome chance grew twice and more. CONCLUSIONS: According to sensitivity analysis and this meta-analysis results reamberin may be positioned as adjuvant energetic protector valid to improve effectiveness of pharmacologic correction during the treatment of emergencies joint with hypoxia, energy deficiencies and vegetative disregulations.

[Metaanalytic Approach to Evaluate Clinical Effectiveness of Infusion Succinnate-Containing Remaxol in Liver Pathologies of Diverse Genesis].

Metaanalysis was applied to the published data on the randomized clinical trials of Remaxol in the treatment of various diseases associated with the liver injury: chronic hepatitis B and C, severe ethanol intoxication, drug-induced pathologies due to tuberculosis chemotherapy, leptospirosis, psoriasis, tumor polychemotherapy. The database included information on 2250 patients. The total number of the patients of the control group (n = 1099) were treated according to the routine schemes (active placebo) and that of the main group (n = 1151) were additionally treated with Remaxol. Combination of the frequency characteristics of the positive outcomes (% of elimination of the main clinical symptoms and complications) in the patients of the reference groups allowed to estimate the general clinical efficacy of Remaxol, that was equal to 1.75 by the outcome frequency characteristics. The odds ratio of the positive outcomes equaled 5.3 [1.8; 17.0] and the number of the patients needed to treat (NPNT) equaled 8 [6; 14]. Therefore, the infusion Remaxol hepatoprotector based on succinic acid was shown to have statistically and clinically significant therapeutic efficacy in pharmacologic correction of the liver pathologies of diverse genesis.

[The clinical efficacy of a succinate-containing infusion drug during pharmacotherapy for hepatic lesions of varying genesis: results of meta-analysis].

AIM: To pool the published results of trials of the new infusion hepatoprotector remaxol for the integral quantification of the magnitude of its clinical efficacy. SUBJECTS AND METHODS: The authors made a systematized review of the published results of randomized clinical trials of the succinate-containing infusion hepatoprotector remaxol in diseases associated with hepatic lesions (chronic hepatitis B and C, severe ethanol intoxication in the presence of alcohol dependence, drug-induced liver lesion during treatment of tuberculosis, and metabolic syndrome). The pooled database included information on 935 patients. The combined control group (n = 447) received traditional pharmacotherapy drugs (active placebo), the treatment group (n = 628) additionally took remaxol. RESULTS: Meta-analysis of the frequency characteristics of positive outcomes (the rate of disappearance of major clinical symptoms and complications) and the activity range for the enzymes characterizing hepatocyte cytolysis (alanine aminotransferase and aspartate aminotransferase) and cholestasis (alkaline phosphatase and gamma-glutamate transpeptidase) in the compared groups could provide an integral evaluation of the clinical efficacy of remaxol, which was 1.57 for enzymatic activity and 1.78 for the frequency characteristics of outcomes. The odds ratio of positive outcomes was 2.9 (range 1.9 to 3.9) and the number of patients who needed to be treated with remaxol during the follow-up to prevent a poor outcome in one patient was 6 (range 4 to 8). CONCLUSION: The succinic acid-based infusion hepatoprotector remaxol provides a statistically and clinically significant therapeutic effect in the drug correction of hepatic lesions of varying genesis.

[Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders]. / Metaanaliticheskaia otsenka klinicheskoi éffektivnosti tsitoflavina pri nevrologicheskikh zabolevaniiakh.

AIM: To carry out an integral quantitative assessment of the clinical efficacy of parenteral use of cytoflavin in treatment of patients with CNS disorders based on the systemic selection of published controlled clinical trials and their meta-analysis. MATERIAL AND METHODS: Twenty-one high evidence-based studies on the efficacy of parenteral use of cytoflavin in different CNS disorders (4314 patients) have been analyzed. Comparisons with basic treatment groups were undertaken to clarify the drug clinical effects adjusted for heterogeneity and variability of response parameters. RESULTS AND CONCLUSION: An analysis of formalized efficacy indicators (increase in the absolute and relative value, odds ratio (OR) etc.) has demonstrated the advantages of cytoflavin. Group combination has increased the statistical power of the meta-analysis. Two models with fixed (Mantel-Haenszel amendment) and random effects were used. All the estimation protocols in different clinical groups of patients with neurologic diseases provided similar results and confirmed the stability of calculated values irrespective of heterogeneity of data arrays. OR of positive outcomes in neuropathologies treated with cytoflavin was 3,02 with χ2 heterogeneity 427,3 and p = 0,000…, I2= 85,7% (82%; 88%).

[Effectiveness and safety of rufinamide at treatment of epilepsy with complications and drug-resistant epilepsy (according to meta-analysis data)]. / Effektivnost' i bezopasnost' lecheniya epilepsii rufinamidom (po dannym metaanaliza).

AIM: Meta-analysis was undertaken to evaluate rufinamide safety and effectiveness in numerous heterogeneous groups of patients with severe and drug resistant epileptic disorders. MATERIAL AND METHODS: There were 164 relevant articles available via medico-clinical periodic databases, but only 15 have been chosen suitable for meta-analysis. All together 1847 participants were included into common massive, with Lennox-Gastaut syndrome (LGS) and similar encephalopathy syndromes, and with drug-resistant partial epileptic forms. 1169 were administered rufinamide additionally to typical anti-epileptic medications (experimental group). 686 received treatment with common practice drugs without rufinamide (control group). RESULTS AND CONCLUSION: Patient with more than 50% seizures reduction were more numerous in rufinamide group (χ2=89.7 with р=0.000...; ОR=2.9 with 95% CI 2.3-3.7). Most frequent and statistically reliable complications of rufinamide use were headache/dizziness and nausea/vomiting. Rufinamide is safe and effective for treatment of different epilepsies including LGS and drug-resistant partial seizures. Rufinamide may be used as second-line adjuvant for routine neurologic practice.